Denali Therapeutics Inc. (DNLI) — Revenue
| Fiscal Year | Revenue | Change YoY |
|---|---|---|
| 2025 | $0 | — |
| 2024 | $0 | -100.0% |
| 2023 | $330.53M | +214.6% |
| 2022 | $105.06M | +115.9% |
| 2021 | $48.66M | -85.5% |
| 2020 | $335.56M | +1174.9% |
| 2019 | $26.32M | -79.6% |
| 2018 | $129.10M | — |
| 2017 | $0 | — |
| 2016 | $0 | — |
| Fiscal Year | Revenue | Change YoY |
|---|---|---|
| 2025 | $0 | — |
| 2024 | $0 | -100.0% |
| 2023 | $330.53M | +214.6% |
| 2022 | $105.06M | +115.9% |
| 2021 | $48.66M | -85.5% |
| 2020 | $335.56M | +1174.9% |
| 2019 | $26.32M | -79.6% |
| 2018 | $129.10M | — |
| 2017 | $0 | — |
| 2016 | $0 | — |